InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong · Delayed Price · Currency is HKD 52.70
-0.30 (-0.57%)
Sep 10, 2026, 11:45 AM HKT
InSilico Medicine Cayman TopCo Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 287% year-over-year to $106.3M, with first-ever profitability and a net margin of 50%. Major pharma deals and AI platform expansion drove growth, while the pipeline advanced with novel assets and zero preclinical-to-clinical failures since 2021.
Fiscal Year 2025
-
AI-driven drug discovery advanced with 28 developmental candidates, major deals including a $2.75B Eli Lilly partnership, and expanded AI platform capabilities. Revenue declined due to timing, but software segment grew and cash position remains strong. Multiple clinical and business milestones expected in 2026.